Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of interferon alpha-1b for preparing medicine for preventing and treating upper respiratory tract inflammation

An upper respiratory tract and interferon technology, which is applied in the application field of interferon α1b in the preparation of upper respiratory tract infection prevention and treatment drugs, and achieves the effect of convenient application

Inactive Publication Date: 2006-03-08
BEIJING TRI PRIME GENE PHARMA CO LTD +1
View PDF0 Cites 8 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Since interferon α2 will produce the above-mentioned toxic and side effects when instilled in the nose, there is currently no interferon used for the prevention and treatment of upper respiratory tract infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Incubate at 37°C for 24 hours, add rhinovirus, and rhinovirus is diluted 10 times to 10 concentrations, 3 wells per concentration, 100 μl per well. Normal cells were used as controls. Culture at 37°C for 5-7 days. Observation Disease Example 1: Inhibitory and Preventive Effects of Interferon on Rhinovirus

[0032] In cultured cervical cancer passage cells (Hela), the inhibitory and preventive effects of interferon α1b and α2b on rhinovirus were detected by cytopathic inhibition method (CPE). Among them, the recombinant human interferon α1b is produced by Beijing Sanyuan Gene Engineering Co., Ltd., and the product name is Yundesu; the recombinant human interferon α2b is produced by Tianjin Hualida Bioengineering Co., Ltd., and the product name is Anfulong; the rhinovirus is from China Microbial Culture Collection Management Center, batch number 20031205. The test is carried out as follows:

[0033] 1. Determination of half infection concentration of virus

[0034] H...

Embodiment 2

[0038] Embodiment 2: the inhibitory effect of interferon to respiratory syncytial virus (RSV)

[0039] Hep-2 cells were seeded in 24-well cell culture plates, and the plaque inhibition test was performed when the cell density reached 80-90%. Doubling dilution of interferon from the stock solution, inoculate 0.2ml / cell well for each dilution, discard after absorbing overnight; wash the plate twice with PBS, dilute the virus solution to 20-50pfu / 0.2ml / cell well, Inoculate the cell culture plate, discard it after absorbing for 2 hours in a 33°C, 5% CO2 incubator, add cell maintenance solution containing 0.8% low-melting point agarose, and culture in a 33°C, 5% CO2 incubator.

[0040] The drug concentrations of recombinant human interferon α1b and α2b inhibiting 50% plaque formation were 10.4ng / ml and 10.96ng / ml respectively.

Embodiment 3

[0041] Embodiment 3: the inhibitory action of interferon to parainfluenza virus

[0042] In cultured dog kidney epithelial cells (MDCK), the inhibitory effect of IFNα-1b on parainfluenza virus was detected by hemadsorption inhibition test.

[0043] The MDCK cells were inoculated in the cell culture tube, and when the cell density reached 80-90%, the in vitro anti-parainfluenza virus pharmacodynamic evaluation experiment of the drug was carried out. First, start with the doubling dilution from the interferon stock solution, inoculate 0.2ml / tube of cells at each dilution, discard after absorbing overnight; after washing twice with PBS, select 100TCID50 virus to inoculate the cell culture tube, and inoculate 0.2ml in each tube, After adsorption at 33°C for 2 hours, replace with cell maintenance solution, and culture at 33°C.

[0044] The lesions were observed daily until the fifth day, and the antiviral effect of the drug was determined by the hemadsorption inhibition test, and ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to an application of recombinant human interferon alpha Ib in preparation of medicine for preventing and curing viral infection of upper respiratory tract and reducing or eliminating one or several side effects related to applied other interferon. Said invention also relates to a recombinant human interferon alpha Ib spray used for above-mentioned application, in the aqueous solution whose total volume is 1000 ml it includes interferon alpha Ib with therapeutic effective dose; 2.5-27.0g of sodium chloride; 5-50mM of phosphoric acid buffer solution, its pH value is 5.7-8.0; 0.01-2g of benzalkonium chloride and 5-20g of human serum albumin.

Description

technical field [0001] The present invention relates to the application of recombinant human interferon alpha 1b in the preparation of medicines for preventing and treating upper respiratory tract infection caused by viruses, and also relates to a spray of recombinant human interferon alpha 1b. Background technique [0002] Upper respiratory tract infection is the most common infectious disease of the respiratory tract. Pathogens mainly invade the nose, nasopharynx and pharynx, leading to different clinical symptoms, such as common cold, acute viral pharyngitis, laryngitis and bronchitis. The common pathogens of upper respiratory tract infection are viruses, about 70% to 80% are caused by viruses, and a few are caused by bacteria. The virus types mainly include rhinovirus, coronavirus, influenza virus, parainfluenza virus, respiratory syncytial virus, adenovirus, etc. Among them, rhinovirus and coronavirus are the main causes of the common cold. Studies have shown that 30-5...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/21A61K9/12A61P31/12A61P31/16A61P11/00
Inventor 刘金毅刘永全孙俭波程永庆
Owner BEIJING TRI PRIME GENE PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com